Aspects of allograft rejection, IV: Evaluation of new pharmacologic agents for prevention of allograft rejection

Chan, 1990, Principles of immunosuppression, Crit Care Clin, 6, 841, 10.1016/S0749-0704(18)30342-7 Gjertson, 1991, Survival trends in long-term first cadaver-donor kidney transplants, 225 Dunn, 1990, Problems related to immunosuppression: Infection and malignancy occurring after solid organ transplantation, Crit Care Clin, 6, 955, 10.1016/S0749-0704(18)30348-8 Leichtman, 1988, Therapeutic approach to renal transplantation: Triple therapy and beyond, Transplant Proc, 20, 1 Platz, 1991, RS-61443: A new, potent immunosuppressivc agent, Transplantation, 51, 27, 10.1097/00007890-199101000-00003 Ullmann, 1983, Characterization of mutant murine lymphoma cells with altered inositate dehydrogenase activity, J Biol Chem, 258, 523, 10.1016/S0021-9258(18)33286-1 Lucas, 1983, Purine metabolism in myeloid precursor cells during maturation, J Clin Invest, 72, 1889, 10.1172/JCI111152 Cohen, 1981, Guanine nucleotide depletion and toxicity in mouse T lymphoma (S-49) cells, J Biol Chem, 256, 8713, 10.1016/S0021-9258(19)68902-7 Lui, 1984, Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin, J Biol Chem, 259, 5078, 10.1016/S0021-9258(17)42958-9 Skoloski, 1986, Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5′-monophosphate dehydrogenase, Cancer Res, 46, 2314 Allison, 1977, The role of “de novo” purine synthesis in lymphocyte transformation, 48, 207 Allison, 1975, Immunological observations on patients with the Lesch-Nyhan syndromes and on the role of “de novo” purine synthesis in lymphocyte transformation, Lancet, 2, 1179, 10.1016/S0140-6736(75)92661-6 Platz, 1991, Prolongation of dog renal allograft survival by RS-61443, a new, potent immunosuppressive agent, Transplant Proc, 23, 497 Kahane, 1989, Cyclosporine, N Engl J Med, 321, 1725, 10.1056/NEJM198912213212507 Häyry, 1995, Aspects of allograft rejection. I. Molecular pathology of acute and chronic rejection, Transplant Rev, 9, 113, 10.1016/S0955-470X(95)80020-9 Makowka, 1993, The development of brequinar as an immunosuppressivc drug for transplantation, Immunol Rev, 136, 51, 10.1111/j.1600-065X.1993.tb00654.x Napoli, 1992, Immunosuppressive agents for the 1990s, J Int Fed Clin Chem, 4, 15 Reed, 1988, Regulation of gene expression in lectin-stimulated or lymphokine-stimulated T lymphocytes, Transplantation, 46, 85S, 10.1097/00007890-198808001-00016 Batiuk, 1995, Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients, Transplantation, 10.1097/00007890-199505270-00007 Batiuk, 1994, What is the dose-response curve for the effects of cyclosporine on calcineurin and cytokine induction in vivo?, Transplant Proc, 26, 2835 1994, A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation, N Engl J Med, 331, 1110, 10.1056/NEJM199410273311702 Jordan, 1994, FK506 “rescue” for resistant rejection of renal allografts under primary cyclosporine immunosuppression, Transplantation, 57, 860, 10.1097/00007890-199403270-00016 Chung, 1992, Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kD S6 protein kinases, Cell, 69, 1227, 10.1016/0092-8674(92)90643-Q Kuo, 1992, Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase, Nature, 358, 70, 10.1038/358070a0 Dumont, 1994, Relationship between multiple biologic effects of rapamycin and the inhibition of pp70S6 protein kinase activity, J Immunol, 152, 992, 10.4049/jimmunol.152.3.992 Sabatini, 1994, RAFTI: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs, Cell, 78, 35, 10.1016/0092-8674(94)90570-3 Brown, 1994, A mammalian protein targeted by G1-arresting rapamycin-receptor complex, Nature, 369, 756, 10.1038/369756a0 Munn, 1994, Renal transplantation: Is the impact of new molecules acting on the immune system already clinically measurable?, J Nephrol, 6, 6 Dayton, 1992, Comparison of the effects of mizoribine with those of azathioprine, 6-Mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotidc metabolism, Mol Pharmacol, 41, 671 Suzuki, 1994, FK506 and deoxyspergualin: Experimental studies and clinical applications, Transplant Immunol, 2, 190, 10.1016/0966-3274(94)90060-4 Greene, 1995, Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide, Biochem Pharmacol, 10.1016/0006-2952(95)00255-X